These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Clinical study of a low-dose contraceptive--Femodene]. Rachev E; Damianov L; Dukovski A; Katsarova M Akush Ginekol (Sofiia); 1995; 34(3):71-3. PubMed ID: 8787249 [TBL] [Abstract][Full Text] [Related]
4. [Clinical evaluation of desogestrel, the first new-generation progestagen, practil 21, on 13,290 women and 74,967 cycles]. Bilotta P; Favilli S Minerva Ginecol; 1987 Dec; 39(12):855-69. PubMed ID: 3329705 [No Abstract] [Full Text] [Related]
5. [Clinical study of the low dose oral contraceptive novynette]. Uchikova E; Milchev N Akush Ginekol (Sofiia); 2003; 42(4):15-6. PubMed ID: 14577362 [TBL] [Abstract][Full Text] [Related]
6. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives]. Cianci A; De Leo V Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832 [TBL] [Abstract][Full Text] [Related]
8. [Clinical study of two monophase oral contraceptives with desogestrel]. Uchikova E; Milchev N; Markova D; Batashki I; Gŭrova A Akush Ginekol (Sofiia); 2007; 46(2):18-21. PubMed ID: 17469446 [TBL] [Abstract][Full Text] [Related]
9. [Laboratory and clinical study with a new progestagen combined with ethinyl estradiol used in contraception]. Galán G; Gayán P; Tisné L Rev Chil Obstet Ginecol; 1985; 50(4):317-24. PubMed ID: 2953049 [No Abstract] [Full Text] [Related]
10. Prospective, open-label, noncomparative study to assess cycle control, safety and acceptability of a new oral contraceptive containing gestodene 60 microg and ethinylestradiol 15 microg (Minesse). Barbosa IC; Filho CI; Faggion D; Baracat EC Contraception; 2006 Jan; 73(1):30-3. PubMed ID: 16371291 [TBL] [Abstract][Full Text] [Related]
11. Clinical experience with a low-dose oral contraceptive containing gestodene. Düsterberg B; Brill K Adv Contracept; 1990 Dec; 6 Suppl():37-49; discussion 50. PubMed ID: 2291446 [TBL] [Abstract][Full Text] [Related]
12. [Acceptability and secondary effects of a new oral contraceptive containing ethinylestradiol and gestodene]. Cremer P; Vekemans M Rev Med Brux; 1987 Nov; 8(9):440-6. PubMed ID: 3423522 [No Abstract] [Full Text] [Related]
16. [Our experience with the use of the contraceptive preparations Femovan and Triquilar from the Schering firm]. Milchev N; Terzhumanov R; Grozdanov G; Krumov G Akush Ginekol (Sofiia); 1992; 31(2):42-3. PubMed ID: 1342561 [No Abstract] [Full Text] [Related]
17. The transdermal contraceptive patch: a new approach to hormonal contraception. Burkman RT Int J Fertil Womens Med; 2002; 47(2):69-76. PubMed ID: 11991433 [TBL] [Abstract][Full Text] [Related]
18. [The effect of two low dose oral contraceptive with gestodene on the systems of natural inhibitors of coagulation]. Uchikova E; Terzhumanov R; Milchev N; Iacheva T Akush Ginekol (Sofiia); 2004; 43(6):19-23. PubMed ID: 15669648 [TBL] [Abstract][Full Text] [Related]
19. Comparison profiles of cycle control, side effects and sexual satisfaction of three hormonal contraceptives. Sabatini R; Cagiano R Contraception; 2006 Sep; 74(3):220-3. PubMed ID: 16904415 [TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of a new oral contraceptive containing drospirenone. Shulman LP J Reprod Med; 2002 Nov; 47(11 Suppl):981-4. PubMed ID: 12497672 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]